Answer
Breastfeeding should be discontinued during each Lemtrada (alemtuzumab) treatment course and for 4 months after its last infusion; however, the benefits of immunity conferred through breast milk may outweigh the risks of potential alemtuzumab exposure to the newborn or infant.
Sources for this answer
- LEMTRADA 12 mg concentrate for solution for infusionSANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 3Document updated
Sources checked